 Passage Bio, Inc. PASG, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the U.S. Food and Drug Administration FDA has granted Rare Pediatric Disease RPD designation to PBGM01 broadly for the treatment of GM1 gangliosidosis. PBGM01 is an AAV-delivery gene therapy currently being developed for the treatment of infantile GM1 gangliosidosis GM1 and has previously been granted Orphan Drug designation. 